Delta Sleep-Inducing Peptide
DSIP is a naturally occurring neuropeptide that actively drives the brain into deep delta-wave sleep, the most physically restorative phase during which growth hormone peaks, tissue repair occurs, and memories consolidate. Unlike pharmaceutical sleep aids, it does not distort sleep architecture or cause dependence, and it also normalises the cortisol rhythm that controls the entire sleep-wake cycle.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
30 mg
Format
Injectable
Composition
10 mg/ml per ml
DSIP modulates neurotransmitter activity across multiple systems: it increases GABA-A receptor sensitivity, reduces noradrenergic tone (reducing arousal), and normalises cortisol and ACTH secretion rhythms: all of which contribute to sleep onset and deep sleep maintenance. It promotes the entry into and duration of NREM stage 3 (delta wave sleep), during which GH secretion is highest and cellular repair processes are most active. DSIP also demonstrates direct antioxidant properties, inhibits stress-induced anxiety through limbic system modulation, and has been studied for use in chronic pain, opiate withdrawal, and circadian rhythm normalisation.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
DSIP specifically promotes NREM stage 3 (slow-wave, delta-wave) sleep: the deepest and most physiologically restorative phase. During delta sleep, GH secretion peaks, tissue repair is most active, immune restoration occurs, and memories consolidate. DSIP is the only peptide specifically shown to actively drive entry into and duration of delta-wave sleep.
Unlike pharmaceutical sleep agents that sedate or distort sleep architecture, DSIP promotes natural sleep stages. Users report subjectively deeper sleep with normal REM cycling: waking feeling genuinely rested rather than pharmacologically suppressed.
DSIP normalises the circadian pattern of cortisol and ACTH secretion: resetting the HPA axis rhythm that governs the energy/sleep/wake cycle. This makes it relevant not just for acute sleep but for chronic sleep-wake cycle dysregulation and jet-lag recovery.
By increasing delta-wave sleep duration, DSIP naturally restores the nocturnal GH pulse that occurs predominantly during this sleep phase. This amplified GH release supports tissue repair, fat metabolism, and cognitive restoration during sleep.
Beyond sleep, DSIP has demonstrated direct anxiolytic effects, antioxidant activity, and stress-buffering properties in preclinical and clinical research. These properties make it relevant for daytime stress management and not solely as an evening sleep compound.
DSIP has been studied in withdrawal contexts, where its ability to normalise cortisol and ACTH rhythm, reduce anxiety, and restore deep sleep addresses multiple dimensions of the withdrawal syndrome: particularly the sleep disruption that characterises early recovery.
Explore selected publications on Delta Sleep, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Preclinical study
Research relevant to Delta Sleep
Publication and key finding
The study reports that the study underscores DSIP-CBBBP potential in correcting neurotransmitter dysregulation and promoting sleep, hinting at its utility in sleep-related therapies.
Frontiers in pharmacology
Evidence type
Human randomized study
Direct Delta Sleep evidence
Publication and key finding
The study reports that one measure of subjectively estimated tiredness decreased within the DSIP group.
Neuropsychobiology
Evidence type
Review
Direct Delta Sleep evidence
Publication and key finding
The study reports that since the turn of the century, it has been postulated that humoral factors induce sleep.
Neuroscience and biobehavioral reviews
Evidence type
Human clinical study
Direct Delta Sleep evidence
Publication and key finding
This publication reports research findings relevant to opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial.
Journal of clinical psychopharmacology
Evidence type
Human clinical study
Direct Delta Sleep evidence
Publication and key finding
The study reports that the number of nocturnal awakenings, non-rapid-eye-movement (NREM) sleep latency, total waking time and waking time after sleep onset were decreased under DSIP treatment, but no significant differences were found in comparison to baseline or to double-blind placebo nights.
International journal of clinical pharmacology research
Combinations used in research protocols where Delta Sleep complements other compounds.
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
DSIP has a generally favourable profile across published studies. It is an endogenous nonapeptide naturally present in human plasma. The most commonly reported effects are mild and transient: expected drowsiness, occasional morning grogginess at higher doses that resolves with dose reduction, and rare headache. Unlike benzodiazepine or Z-drug sleep agents, DSIP is not associated with respiratory depression, dependency, or tolerance in the available research. No significant cardiovascular, renal, or hepatic effects have been documented. Cycling is recommended to maintain peptide sensitivity.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
